TransCode Therapeutics, Inc.
NASDAQTransCode Therapeutics heads into the back half of May carrying a 26% one-month price loss, a freshly filed shelf registration, and short interest that has just ticked back up after a multi-week retreat. The most significant catalyst context is the April 30 S-1 filing. TransCode registered up to 15.96 million shares for resale by selling stockholders — a large number relative to a…
Snapshot as of 16 May 2026
TransCode Therapeutics heads into the back half of May carrying a 26% one-month price loss, a freshly filed shelf registration, and short interest that has just ticked back up after a multi-week retreat. The most…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for RNAZ — free to start on ORTEX.
Sign up for free →Open RNAZ on ORTEX